You can access any of the podium or poster presentations’ abstracts by searching for it below. For the 2026 FIP world congress in Montreal, presentations and summaries from invited speakers are available below, while abstracts are published in the Pharmacy Education Journal (PEJ) here.
Export this Abstract | Print this Abstract |
Add to my preferred Abstracts list |
My preferred Abstracts list (50) |
Back to Search
GRANTING BIOWAIVER FOR IMMEDIATE RELEASE SOLID ORAL DOSAGE FORMS OF AMOXICILLIN: RESULTS OF A LITERATURE REVIEW
- In: Poster Session
- At: Düsseldorf (Germany) (2015)
- Type: Poster
- By: THAMBAVITA, Dhanusha (Faculty of Medicine, University of Colombo, Pharmacology, Colombo-08, Sri Lanka)
- Co-author(s): Dhanusha Thambavita
- Abstract:
Biowaiver(BW) monographs pertaining to waiving of in vivo bioequivalence(BE) are available for drugs belonging to Biopharmaceutics Classification System(BCS) class 1 and III. World Health Organization(WHO) classifies amoxicillin to BCS class 1 but no BW monograph is available as yet. We reviewed literature relevant to a BW monograph for..
The access to the whole abstract and if available the presentation file is available to FIP members and to congress participants of that specific congress.
Please login
Last update 23 September 2026